1The Non-Hodgkin's Lymphoma Classification Project.A clinical evaluation of the International Lymphoma Study Group classication of non-Hodgkin's lymphoma[J].Blood,1997,89(11):3909-3918. 被引量：1
2Vose JM.International Peripheral T-cell Lymphoma(PTCL)Clinical and Pathologic Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines[J].Blood,2005,1006(11):239. 被引量：1
4Delves PJ,Roitt IM.The immune system.Second of two parts[J].N Engl J Med,2000,343(2):108-117. 被引量：1
5Delves PJ,Roitt IM.The immune system.First of two parts[J].N Engl J Med,2000,343(1):37-49. 被引量：1
6Stein H,Foss HD,Durkop H,et al.CD30(+)anaplastic large cell lymphoma:a review of its histopathologic,genetic,and clinical features[J].Blood,2000,97(12):3681-3695. 被引量：1
7Chen CY,Yao M,Tang JL,et al.Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan:with special reference to T-cell lymphoma[J].Ann Oncol,2004,15(7):1091-1096. 被引量：1
8Martinez-Delgado B,Cuadros M,Honrado E,et al.Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas[J].Leukemia,2005,19(12):2254-2263. 被引量：1
9Ralfkiaer E,Muller-Hermelink HK,Jaffe ES.Peripheral T-cell lymphoma,unspecified[A].Jaffe ES,Harris NL,Stein H,et al.World Health Organization classification of tumours.Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M].Lyon:IARC Press,2001:227-229. 被引量：1
10Armitage JO,Cavalli F,Zucca E,eds.Text atlas of lymphomas(revised edition)[M].London:Martin Dunitz,2002:30-43. 被引量：1
4Adams J. The proteasome : a suitable antineoplastic target [ J ]. Nat Rev Cancer, 2004,4(5) :349-360. 被引量：1
5Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J]. Cancer Cell Int, 2005,5(1) :18. 被引量：1
6Paramore A, Frantz S. Bortezomib [ J ]. Nat Rev Drug Discov, 2003,2(8) :611-612. 被引量：1
7Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the protea- some inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer [ J 1. J Clin On- col, 2004,22(11) :2108-2121. 被引量：1
8Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of protea- some inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin's lymphoma[ J]. J Clin Oncol, 2005,23 (4):667-675. 被引量：1
9Fisher RI, Bernstein SH, Kahl BS, et al. Muhicenter phase Ⅱstudy of bortezomib in patients with relapsed or refractory mantle cell lymphoma [ J ]. J Clin Oncol, 2006,24 (30) :4867 4874. 被引量：1
10Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the muhicenter phase 2 PINNACLE study [ J]. Ann Oncol, 2009,20(3) :520-525. 被引量：1
